Stock Market's Major German Index Displaying Signs of Fatigue
DAX Pauses After Record High, Focus on Rheinmetall and Fresenius Medical Care
The DAX, Germany's blue-chip index, has taken a brief respite following its recent high, trading 0.3 percent lower at 22,551 points as of Friday. On Thursday, the index hit a new record high of 22,624 points, marking a solid weekly gain of around three percent.
The Euro Stoxx 50, another significant European index, shows slightly more positive momentum, trading 0.2 percent higher at 5,512 points.
The latest surge in the DAX was primarily driven by optimism towards diplomatic progress in the Ukraine conflict, particularly after the phone call between U.S. President Donald Trump and Russian President Vladimir Putin. However, skepticism has been growing among investors, with portfolio manager Thomas Altmann of QC Partners questioning the market's technical health.
Capital market expert Jürgen Molnar of Robomarkets shares the sentiment, suggesting that investors are caught between hope for a ceasefire and concerns about increased tensions, not only between the U.S. and Russia, but also between Trump and the European Union, particularly in trade policy. Despite these uncertainties, the stock market has so far demonstrated remarkable resilience.
Two particular stocks standing out in the DAX today are Rheinmetall and Fresenius Medical Care.
Rheinmetall's shares have seen a sharp increase of 8.5 percent, leading the winners' list in the DAX. The surge in interest is linked to the Munich Security Conference, where discussions about the new U.S. government's foreign policy orientation in the Ukraine conflict are centerstage. U.S. Vice President J.D. Vance, in an interview with the Wall Street Journal, expressed a desire for a peace agreement that secures Ukraine's long-term independence, while also stating a belief in an agreement that might surprise many.
In contrast, Fresenius Medical Care shares have plummeted by around five percent. The decline in the share price is attributed to weak news from US competitor DaVita. JPMorgan analyst David Adlington described DaVita's latest outlook as "somewhat weak," which has dampened the mood at Fresenius Medical Care.
[Enrichment Data: Rheinmetall's shares have been attracting attention due to rising defense spending in Europe, heightened geopolitical tensions, and ongoing discussions about tariffs and military support to Ukraine and NATO allies. Defense budgets are expected to continue rising, especially as markets await clarity on new tariffs and further defense commitments from European governments. However, even defense stocks can experience volatility during times of increased political uncertainty.]
[Enrichment Data: Fresenius Medical Care’s shares have gained interest due to a mix of positive corporate results and ongoing market speculation about healthcare sector resilience or recovery. The company is a leading provider of dialysis products and services, which remain essential regardless of economic cycles.]
Sources: dpa AFX
[Also read: Goldman Sachs sees stock rally for 2025: There is only one big problem for investors]
[Or: Was that it with the stock rally? Experts surprise with interest rate forecast for 2025]
Investors might find opportunities in the finance sector, particularly with businesses like Rheinmetall, given the increasing defense spending in Europe and the geopolitical tensions that might lead to further defense commitments from European governments. On the opposite side, the investing landscape could be influenced by the declining share price of Fresenius Medical Care, which has been attributed to weak news from its US competitor DaVita.
